|
|
|
Volumn 18, Issue 4 Spec No., 2012, Pages
|
|
Treatment and cost implications of pertuzumab.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
MONOCLONAL ANTIBODY;
PERTUZUMAB;
ARTICLE;
BREAST TUMOR;
DRUG ANTAGONISM;
DRUG COST;
ECONOMICS;
FEMALE;
HEALTH CARE COST;
HUMAN;
PHASE 3 CLINICAL TRIAL (TOPIC);
RANDOMIZED CONTROLLED TRIAL (TOPIC);
UNITED STATES;
ANTIBODIES, MONOCLONAL, HUMANIZED;
BREAST NEOPLASMS;
CLINICAL TRIALS, PHASE III AS TOPIC;
DRUG COSTS;
FEMALE;
HEALTH CARE COSTS;
HUMANS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RECEPTOR, ERBB-2;
UNITED STATES;
|
|
EID: 84874441029
PISSN: None
EISSN: 19362692
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (3)
|
|
References (0)
|
